Lowering Homocysteine Decreases Levels and Expression of VEGF165 and Endostatin

Journal of Surgical Research

Volumn 146, Issue 2, 2008, Pages 202-210

  Atta, Hussein M ^a   El Rehani, Mahmoud A ^a   Raheim, Salama Abdel ^a   Galal, Abdel Moneim F ^a  

^a Minia University   (Egypt)

Author keywords

angiogenesis; diabetes mellitus; endostatin; homocysteine; peripheral arterial disease; vascular endothelial growth factor

Indexed keywords

CYANOCOBALAMIN; ENDOSTATIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; THIAMINE; TRI B; UNCLASSIFIED DRUG; VASCULOTROPIN 165;

ADULT; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; DIABETES MELLITUS; DOWN-REGULATION; ENDOSTATINS; FEMALE; FOLIC ACID; GENE EXPRESSION; HOMOCYSTEINE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERIPHERAL VASCULAR DISEASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAMINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN B COMPLEX;

EID: 41649101413     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.04.038     Document Type: Article

References (74)

1. Simmons M. Angiogenesis. Where do we stand now?. Circulation 111 (2005) 1556
2. Losordo D.W., and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease part I: Angiogenic cytokines. Circulation 109 (2004) 2487
3. Felmeden D.C., Blann A.D., and Lip G.Y.H. Angiogenesis: Basic pathophysiology and implications for disease. Eur Heart J 24 (2003) 586
4. Seko Y., Fukuda S., and Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci (Lond) 106 (2004) 439
5. Taylor L.M., Moneta G.L., Sexton G.J., et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29 (1999) 8
6. van Guldener C., and Stehouwer C.D.A. Hyperhomocysteinemia and vascular disease-a role for DNA hypomethylation?. Lancet 361 (2003) 1668
7. Lee R., and Frenkel E.P. Hyperhomocysteinemia and thrombosis. Hematol Oncol Clin N Am 17 (2003) 85
8. The homocysteine studies collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 288 (2002) 2015
9. Bostom A.G., Rosenberg I.H., Silbershatz H., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med 131 (1999) 352
10. Malinow M.R., Bostom A.G., and Krauss R.M. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 99 (1999) 178
11. Chambers J.C., Ueland P.M., Wright M., et al. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 89 (2001) 187
12. Chambers J.C., Obeid O.A., and Kooner J.S. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 19 (1999) 2922
13. Bellamy M.F., McDowell I.F.W., Ramsey M.W., et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98 (1998) 1848
14. Bellamy M.F., McDowell I.F., Ramsey M.W., et al. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 29 (1999) 659
15. Chambers J.C., Ueland P.M., Obeid O.A., Wrigley J., Refsum H., and Kooner J.S. Improved Vascular Endothelial Function After Oral B Vitamins An Effect Mediated Through Reduced Concentrations of Free Plasma Homocysteine. Circulation 102 (2000) 2479
16. Woo K.S., Chook P., Lolin Y.I., et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 34 (1999) 2002
17. Duan J., Murohara T., Ikeda H., et al. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol 20 (2000) 2579
18. Makin A.J., Chung N.A.Y., Silverman S.H., et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis?. Clin Sci 104 (2003) 397
19. Roybal C.N., Yang S., Sun C.W., et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 279 (2004) 14844
20. Noma H., Funatsu H., Yamashita H., et al. Regulation of angiogenesis in diabetic retinopathy: Possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 120 (2002) 1075
21. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4
22. Gaudry M., Bregerie O., Andrieu V., et al. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 90 (1997) 4153
23. Khurana R., Simons M., Martin J.F., et al. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation 112 (2005) 1813
24. Cucina A., Borrelli V., Randone B., et al. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. J Surg Res 109 (2003) 16
25. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98 (1998) 2108
26. Matsui K., Yoshioka T., Murakami Y., et al. Serum concentrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease. Circ J 67 (2003) 660
27. Roller R.E., Renner W., Dorr A., et al. Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease. Thromb Haemostasis 85 (2001) 368
28. Nakajima K., Tabata S., Yamashita T., et al. Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease. Clin Cardiol 27 (2004) 281
29. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: Relationship to VEGF, glycemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180 (2005) 113
30. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: Endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277
31. Moulton K.S., Heller E., Konerding M.A., et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1726
32. Marneros A.G., and Olsen B.R. Physiological role of collagen XVIII and endostatin. FASEB J 19 (2005) 716
33. Ferreras M., Felbor U., Lenhard T., et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486 (2000) 247
34. Dixelius J., Larsson H., Sasaki T., et al. Endostatin induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95 (2000) 3403
35. Yamaguchi N., Anand-Apte B., Lee M., et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18 (1999) 4414
36. Buysschaert M., Dramais A.-S., Wallemacq P.E., et al. Hyperhomocysteinemia in Type 2 Diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23 (2000) 1816
37. Quinlivan E.P., McPartlin J., McNulty H., et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 359 (2002) 227
38. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47 (2001) 617
39. Funatsu H., Yamashita H., Noma H., et al. Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci 44 (2003) 1042
40. Feldman A.L., Alexander Jr. H.R., Bartlett D.L., et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 8 (2001) 741
41. Feldman A.L., Tamarkin L., Paciotti G.F., et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6 (2000) 4628
42. Koehne P., Willam C., Strauss E., et al. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol 279 (2000) H817
43. Kohkichi H., Ritsuto F., and Kohji M. Expression of the endostatin gene in epithelial ovarian cancer. Clin Cancer Res 7 (2001) 2405
44. Taylor L.M., DeFrang R.D., Harris E.J., et al. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13 (1991) 128
45. Darius H., Pittrow D., Haberl R., et al. Are elevated homocysteine plasma levels related to peripheral arterial disease?. Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest 33 (2003) 751
46. Malinow M.R., Kang S.S., Taylor L.M., et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 79 (1989) 1180
47. Chambers J.C., and Kooners J.S. Homocysteine-an innocent bystander in vascular disease?. Eur Heart J 22 (2001) 717
48. Ciccarone E., Di Castelnuovo A., Assanelli D., et al. Homocysteine levels are associated with the severity of peripheral arterial disease in type 2 diabetic patients. J Thromb Haemost 1 (2003) 2540
49. Huang E.J., Kuo W.W., Chen Y.J., et al. Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 366 (2006) 293
50. Weiss N., Zhang Y.-Y., Heydrick S., et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci USA 98 (2001) 12503
51. Tawakol A., Omland T., Gerhard M., et al. Hyperhomocyst(e) inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95 (1997) 1119
52. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98 (1996) 5
53. Au-Yeung K.K., Woo C.W., Sung F.L., et al. Hyperhomocysteinemia activates nuclear factor-κB in endothelial cells via oxidative stress. Circ Res 94 (2004) 28
54. Zhang C., Cai Y., Adachi M.T., et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276 (2001) 35867
55. Hossain G.S., van Thienen J.V., Werstuck G.H., et al. TDAG51 Is induced by homocysteine, promotes detachmentmediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278 (2003) 30317
56. Lee S.J., Kim K.M., Namkoong S., et al. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem 280 (2005) 5781
57. Maeda M., Yamamoto I., Fujio Y., et al. Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages. Biochim Biophys Acta 1623 (2003) 41
58. Holven K.B., Holm T., Aukrust P., et al. Effect of folic acid treatment on endothelium-dependent vasodilatation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med 110 (2001) 536
59. Mangoni A.A., Sherwood R.A., Asonganyi B., et al. Short-term oral acid folic supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 18 (2005) 220
60. Panchal V.R., Rehman J., Nguyen A.T., et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 43 (2004) 1383
61. Smulders Y.M., Rakic M., Slaats E.H., et al. Fasting and post-methionine homocysteine levels in NIDDM determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22 (1999) 125
62. Aiello L.P., and Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77 (2000) S113
63. Shams N., and Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin N Am 19 (2006) 335
64. Looker H.C., Fagot-Campagna A., Gunter E.W., et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 46 (2003) 766
65. Noma H., Funatsu H., Yamashita H., et al. Regulation of angiogenesis in diabetic retinopathy: Possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol 120 (2002) 1075
66. Liou J.Y., Shyu K.G., Lu M.J., et al. Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. J Formos Med Assoc 105 (2006) 377
67. Nagashima M., Asano G., and Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 27 (2000) 2339
68. Kanazawa H., Hirata K., and Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin in emphysema. Eur Respir J 22 (2003) 609
69. Takeshita S., Kawamura Y., Takabayashi H., et al. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol 139 (2005) 575
70. Sandor Z., Deng X.M., Khomenko T., et al. Altered angiogenic balance in ulcerative colitis: A key to impaired healing?. Biochem Biophys Res Commun 350 (2006) 147
71. Gruszka A., Kunert-Radek J., Pawlikowski M., et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary 8 (2005) 163
72. Zhao J., Yan F., Ju H., et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204 (2004) 87
73. Uematsu S., Higashi T., Nouso K., et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20 (2005) 583
74. Miyashita M., Tajiri T., Yanagi K., et al. Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology 50 (2003) 308